Based on these implications, it is crucial to closely monitor SLE patients with anti-Sm, anti-Ro, and anti-RNP positivity for early signs of LN, particularly during the first five years following their SLE diagnosis. This evidence concerns the gene RNPC3 and systemic lupus erythematosus.